



An ECOG Established Oncology Research Network

PrECOG, LLC

1818 Market Street | Suite 1100 | Philadelphia, PA 19103
<http://www.precogllc.org>

ECOG Research and Education Foundation

Who We Are

PrECOG is a not-for-profit limited liability company formed in 2006 by the ECOG Research and Education Foundation, Inc. Through this relationship, key opinion leaders and the entire network of ECOG investigators and institutions underpin PrECOG. Funded entirely outside of the public health system, PrECOG uses an operational structure separate from ECOG for all facets of clinical trial management. PrECOG typically functions as the sponsor and holds the IND, or works under company-owned INDs with transfer of obligations.

We are governed by a Board of Managers that oversees all clinical trial activities.

The board consists of a Chair, Director of Operations, and 5 members of ECOG's Senior Leadership, all prominent in their institutions of primary affiliation.

Our services are governed by Standard Operating Procedures and are fully compliant with ICH/GCP and FDA regulations and guidelines.

Why PrECOG?

Familiarity with the inner workings and leadership of NCI and FDA make us well positioned to:

- Develop and manage phase I-III clinical trials in any area of oncology, from concept through completion
- Expedite clinical trial development through a nimble mechanism
- Initiate start-up activities through parallel operations
- Complete trials within established timelines

PrECOG Board of Managers

Peter J. O'Dwyer	Chair, Board of Managers
Donna Marinucci	Board of Managers
Bruce Giantonio	Board of Managers
Joseph Sparano	Board of Managers
Michael Atkins	Board of Managers
Patrick J. Flynn	Board of Managers
Robert DiPaola	Board of Managers




What Does PrECOG Offer?

- Clinical trial oversight and management of all facets of sponsor-related responsibilities under an IND
- Master contracts with an established network of institutions for efficient start-up and streamlined process across the continuum of study operations
- Leverage strong existing site relationships to facilitate high-quality performance



Accelerated Trial Development with PrECOG



Efficiencies of PrECOG Phase I-III Drug Development Model

Phase I/II

- Aligned with ECOG Disease Committee
- Standardized approach to drug development
- Cost-effective trial model versus CRO model
- Faster completion through experienced sites

Phase III

- Collaboration with key opinion leaders and cooperative group sectors for drug development
- Accelerated start-up

Phase I-III

- Access to consortium of laboratories, which can process molecular markers and tissue banking
- Access to a broad array of sites: universities, medical centers, Community Clinical Oncology Programs (CCOPs), and Cooperative Group Outreach Programs (CGOPs)
- Streamlined drug development processes and timelines through central organization
- Adaptive study management through customized monitoring, central randomization, and EDC

More About PrECOG . . .

- Since PrECOG trials are not NCI funded, they do not require CTEP approval
- Webcasts are utilized for efficiencies at study initiation and for ongoing training
- Enrollment to PrECOG studies is applied to ECOG enrollment credit
- PrECOG maintains a global Data Safety Monitoring Board

Contact Us



For further information regarding PrECOG or submission of concepts, please contact:

Peter J. O'Dwyer, MD, Chair, Board of Managers

1818 Market Street, Suite 1100

Philadelphia, PA 19103

Phone: 215-662-7606

E-mail: peter.odwyer@uphs.upenn.edu

Donna Marinucci, Director of Operations

1818 Market Street, Suite 1100

Philadelphia, PA 19103

Phone: 215-789-3601

E-mail: dmarinucci@precogllc.org



PrECOG, LLC

1818 Market Street | Suite 1100 | Philadelphia, PA 19103
<http://www.precogllc.org>

ECOG Research and Education Foundation